Double-blind crossover trial of bromhexine (Bisolvon) in the treatment of chronic bronchitis.
The results of a double-blind crossover trial of bromhexine (Bisolvon) in the treatment of chronic bronchitis are reported. Benefit was shown by statistically significant changes in the peak expiratory flow rate, ascultatory findings and sputum volume. Benefit was also demonstrated by changes in dyspnoea, sputum, consistency and ease of expectoration, but these were without statistical significance. A review of the literature together with the results of this trial suggest that, when adequate consideration is given to a number of therapeutic variables, Bisolvon will be effective medication for most patients with chronic bronchitis associated with thick, tenacious sputum.